Ningbo David Medical Device Co., Ltd. Class A

Ningbo David Medical Device Co., Ltd. Class A

SSZSE:300314
14.31
CNY
-0.73
(-4.85%)
0.32EPS
40.21P/E
3.70BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A carries a market capitalization of 3.70B, placing it among publicly traded companies globally. Its enterprise value stands at 3.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.70B
Enterprise Value3.08B

Share Statistics

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A has 288.00M shares outstanding.

Shares Outstanding288.00M

Valuation Ratios

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 40.21. The price-to-sales ratio is 6.05, and the price-to-book ratio stands at 2.88.

PE Ratio40.21
PS Ratio6.05
PB Ratio2.88
P/TBV Ratio2.98

Enterprise Valuation

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A trades at an EV/EBITDA multiple of 30.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 30.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.08B versus a market cap of 3.70B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.03
EV / EBITDA30.02
EV / EBIT30.02

Financial Position

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A maintains a current ratio of 4.23, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.36, indicating conservative leverage, while an interest coverage ratio of 345.44 demonstrates strong ability to service its debt obligations.

Current Ratio4.23
Quick Ratio2.79
Debt / Equity0.36
Debt / EBITDA0.04
Interest Coverage345.44

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A posted a return on equity (ROE) of 7.42, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.32 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.40, useful for judging operating efficiency across full business cycles. The company generates approximately 665,945.01 in revenue per employee across its workforce of 920.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.44 indicates how many times Ningbo David Medical Device Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)7.42
Return on Assets (ROA)6.27
Return on Invested Capital (ROIC)7.32
Return on Capital Employed (ROCE)7.40
Revenue Per Employee665,945.01
Employee Count920.00
Inventory Turnover1.44

Taxes

CNY

Over the twelve months ended September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A recorded 11.10M in income tax expense. That works out to an effective tax rate of 10.76, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 103.24M, leaving 92.13M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax11.10M
Effective Tax Rate10.76

Stock Price Statistics

CNY

As of the close on November 17, 2026, Ningbo David Medical Device Co., Ltd. Class A's stock has gained approximately 1.27% over the past 52 weeks. The 50-day moving average sits at 12.94, while the 200-day moving average is 12.10.

52-Week Price Change1.27%
50-Day Moving Average12.94
200-Day Moving Average12.10

Income Statement

CNY

Over the twelve months ended September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A generated 612.67M in revenue and converted that into 92.13M in net income, yielding earnings per share of 0.32. EBITDA reached 102.68M, while operating income came in at 78.29M.

Revenue612.67M
Gross Profit304.87M
Operating Income78.29M
Pretax Income103.24M
Net Income92.13M
EBITDA102.68M
EBIT102.68M
Earnings Per Share (EPS)0.32

Balance Sheet

CNY

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A holds 625.83M in cash and equivalents against 4.60M in total debt, resulting in a net debt position of -550.83M. Total book value stands at 1.29B, with working capital of 722.87M providing operational flexibility.

Cash & Cash Equivalents625.83M
Total Debt4.60M
Net Debt-550.83M
Equity (Book Value)1.29B
Book Value Per Share4.47
Working Capital722.87M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-31.89M

Margins

Over the twelve months ended September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A posted a gross margin of 49.76, reflecting its pricing power and cost economics. The operating margin of 12.78 and net profit margin of 15.04 provide insight into operational efficiency.

Gross Margin49.76
Operating Margin12.78
Pretax Margin16.85
Profit Margin15.04
EBITDA Margin16.76

Stock Splits

Ningbo David Medical Device Co., Ltd. Class A's most recent stock split took place on May 20, 2015 with a 5:9 split ratio.

Last Split Date5/20/2015
Split Ratio5:9

Scores

As of September 30, 2026, Ningbo David Medical Device Co., Ltd. Class A has an Altman Z-Score of 11.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.45